INHX: Profile for Inhibitex, Inc.

Inhibitex, Inc., a biopharmaceutical company, develops differentiated anti-infective products to prevent and treat serious infections primarily shingles and chronic hepatitis C. Its anti- infective product candidates include FV-100, an orally available nucleoside analogue prodrug, which completed Phase I trials used for the treatment of herpes zoster or shingles; and aurexis, a humanized monoclonal antibody, which completed Phase IIa trials used for the treatment of serious S. aureus infections. The companys preclinical product candidates include HCV polymerase inhibitors, which are used for the treatment of chronic HCV infection; HIV integrase inhibitors that are used for the treatment of HIV infection; and staphylococcal vaccines, an active vaccine to prevent S. aureus infections. It has MSCRAMM based license and collaboration agreement with Wyeth Pharmaceuticals for the development of staphylococcal vaccines; and royalty-bearing license agreement with Cardiff University and Katholieke Universiteit for intellectual property of HCV nucleoside polymerase inhibitors. Inhibitex, Inc. was founded in 1994 and is based in Alpharetta, Georgia.

Key Statistics

COMPANY WEBSITES

Home Page

Search Yahoo! for:
More on Inhibitex Inc.

CORPORATE GOVERNANCE

Inhibitex Inc.'s Corporate Governance Quotient (CGQ®) as of 1-Jul-09 is better than 85.7% of CGQ Universe companies and 69.1% of Pharmaceuticals, Biotechnology & Life Sciences companies.

Brought to you by Institutional Shareholder Services.

View Financials

KEY EXECUTIVES

	Pay	Exercised
Mr. Russell H. Plumb M.B.A., 50 Chief Exec. Officer, Pres, Chief Financial Officer, Principal Accounting Officer, Sec., Treasurer and Exec. Director	N/A	N/A
Dr. Joseph M. Patti M.S.P.H., Ph.D., 44 Founder, Chief Scientific Officer, Sr. VP of R&D and Assistant Sec.	N/A	N/A
Dr. Geoffrey W. Henson Ph.d., 61 Sr. VP of Drug Devel.	$ 264.00K	N/A
Dr. Seth V. Hetherington M.D., 56 Chief Medical Officer and VP of Clinical Devel.	N/A	N/A
Mr. Robert T. Schweiger , 63 VP of Bus. Devel.	N/A	N/A

Dollar amounts are as of 31-Dec-08 and compensation values are for the last fiscal year ending on that date. "Pay" is salary, bonuses, etc. "Exercised" is the value of options exercised during the fiscal year.

View Insiders

Add to Portfolio

Set Alert

Email to a Friend

•

Annual Reports

•

Sector Analysis